DS
AVIR icon

David Shaw’s Atea Pharmaceuticals AVIR Stock Holding History

David Shaw’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.61M Sell
345,186
-34,128
-9% -$170K ﹤0.01% 3385
2026
Q1 		$2.04M Sell
379,314
-85,473
-18% -$393K ﹤0.01% 2893
2025
Q4 		$1.66M Buy
464,787
+100,019
+27% +$318K ﹤0.01% 3199
2025
Q3 		$1.06M Buy
364,768
+168,916
+86% +$577K ﹤0.01% 3420
2025
Q2 		$705K Sell
195,852
-148,693
-43% -$443K ﹤0.01% 3465
2025
Q1 		$1.03M Buy
344,545
+88,462
+35% +$276K ﹤0.01% 3069
2024
Q4 		$858K Buy
256,083
+62,505
+32% +$208K ﹤0.01% 3290
2024
Q3 		$648K Buy
193,578
+45,665
+31% +$166K ﹤0.01% 3557
2024
Q2 		$490K Sell
147,913
-59,846
-29% -$223K ﹤0.01% 3636
2024
Q1 		$839K Buy
207,759
+22,582
+12% +$88.4K ﹤0.01% 3207
2023
Q4 		$565K Buy
185,177
+115,228
+165% +$349K ﹤0.01% 3455
2023
Q3 		$210K Sell
69,949
-13,473
-16% -$45.8K ﹤0.01% 3744
2023
Q2 		$312K Buy
83,422
+33,724
+68% +$126K ﹤0.01% 3585
2023
Q1 		$166K Buy
49,698
+9,476
+24% +$38.4K ﹤0.01% 3937
2022
Q4 		$193K Buy
40,222
+11,065
+38% +$56K ﹤0.01% 4258
2022
Q3 		$166K Buy
+29,157
New +$223K ﹤0.01% 4513
2022
Q1 		– Sell
-19,404
Closed -$173K – 5516
2021
Q4 		$173K Buy
+19,404
New +$302K ﹤0.01% 4933
2021
Q2 		– Sell
-28,187
Closed -$1.74M – 4740
2021
Q1 		$1.74M Buy
+28,187
New +$1.9M ﹤0.01% 2708

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

David Shaw's AVIR Position: Q2 2026 in Review

David Shaw reduced its Atea Pharmaceuticals (AVIR) stake by 9% in Q2 2026, selling an estimated $170K and leaving 345,186 shares worth $1.61M. The position accounts for ﹤0.01% of the portfolio, ranked #3385.

David Shaw first reported a position in AVIR in Q1 2021 and has held it in 18 quarters since. The position peaked at $2.04M in Q1 2026. 125 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • David Shaw held 345,186 shares of Atea Pharmaceuticals worth $1.61M as of Q2 2026.
  • David Shaw sold 34,128 Atea Pharmaceuticals shares in Q2 2026, an estimated $170K.
  • Atea Pharmaceuticals made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #3385 holding.
  • David Shaw first reported a position in Atea Pharmaceuticals in Q1 2021 and has held it in 18 quarters since.
  • David Shaw's Atea Pharmaceuticals position peaked at $2.04M in Q1 2026.
  • 125 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.